本文選題：子宮內(nèi)膜癌　切入點：子宮內(nèi)膜增生　出處：《北京協(xié)和醫(yī)學(xué)院》2016年碩士論文

【摘要】：目的：總結(jié)140例連續(xù)大劑量孕激素治療的早期子宮內(nèi)膜癌/內(nèi)膜不典型增生患者中22例接受手術(shù)治療的臨床資料,分析其手術(shù)原因及改行手術(shù)治療的相關(guān)因素及腫瘤結(jié)局。方法：1991年11月至2015年4月北京協(xié)和醫(yī)院收治的早期子宮內(nèi)膜癌/內(nèi)膜不典型增生共140例行連續(xù)口服大劑量孕激素治療,每3個月評估子宮內(nèi)膜變化情況,患者放棄保守治療、治療期間疾病進(jìn)展或出現(xiàn)嚴(yán)重不良反應(yīng)時則隨時轉(zhuǎn)行手術(shù)治療。病理證實完全緩解后予個體化后續(xù)治療。回顧性分析大劑量孕激素治療后行手術(shù)治療的原因及相關(guān)因素。結(jié)果：研究納入89例子宮內(nèi)膜癌(EC)和51例不典型增生(AH),中位年齡31歲。大劑量孕激素治療102例(72.9%)獲CR,11例(7.8%)獲PR,5例(3.6%)SD,1例(0.7%)PD。22例轉(zhuǎn)行手術(shù)治療。中位隨訪時間26(3-151)月。AH組和EC組手術(shù)率分別為11.8%和18.0%(P0.05)：MA組和MPA組手術(shù)率分別為14.5%和16.7%(P0.05)；年齡≤35歲和35歲者手術(shù)率分別為13.3%和41.7%(P0.05)BMI25kg/m2和≥25kg/m2者手術(shù)率分別為10.7%和23.2%(P0.05)。年齡35歲是孕激素治療后手術(shù)治療的高危因素。結(jié)論：早期子宮內(nèi)膜癌／不典型增生連續(xù)口服大劑量孕激素可獲得較高逆轉(zhuǎn)率；年齡35歲是終止保守治療接受手術(shù)治療的重要影響因素。
[Abstract]:Objective : To summarize the clinical data of 22 patients with early endometrial carcinoma / endometrial atypical hyperplasia treated with continuous large - dose gestagen in the early stage of treatment . The causes and related factors of operation were analyzed retrospectively . Results : The results showed that 89 cases of endometrial carcinoma ( EC ) and 51 cases of atypical hyperplasia ( AH ) were treated by operation . Results : The results showed that the operation rates of the patients with advanced endometrial carcinoma ( EC ) and 51 cases were CR , 11 cases ( 0.7 % ) were treated with CR , 11 cases ( 0.7 % ) were treated with PR , 5 cases ( 3.6 % ) SD , 1 ( 0.7 % ) PD . 22 cases underwent surgery . The operative rates of AH and EC were 11.8 % and 18.0 % ( P0.05 ) .
The operative rates of patients aged 鈮，

本文編號：1689820